FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC By Ogkologos - March 18, 2026 66 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Adjuvant Alectinib Significantly Improves Disease-Free Survival in Patients with Resected ALK-positive... April 18, 2024 Blind Customer Surprised With Sweet Message In Braille For Her Birthday August 28, 2021 Woman Finds Out She Has Breast Cancer From Museum Photo Booth November 1, 2019 FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection January 14, 2026 Load more HOT NEWS FDA Approves Sacituzumab Govitecan-hziy for HR-positive Advanced Breast Cancer Selpercatinib Approved for Thyroid and Lung Cancers with RET Gene Alterations Experimental mRNA Vaccine Hints at Potential Against Glioblastoma Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients...
